A phase 3 open-label safety study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide single-tablet regimen in HIV-1 positive patients with mild to moderate renal impairment

Open-label, multicenter, multi-cohort study to assess the safety, tolerability, and efficacy of a STR of E/C/F/TAF in HIV-positive, adult subjects with mild to moderate renal impairment.